ArticleBrain communications2025
Whole-brain volumetric analysis in adult Moyamoya patients reveals significant atrophy compared to healthy controls.
Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multiterritorial tailored revascularization in adult Moyamoya patients: expanding revascularization approaches to ACA and PCA territories.Neurosurgical review · 2026Article
- Identifying Diagnostic Thresholds for the Assessment of Cerebrovascular Reserve Impairment in Moyamoya Disease: COBrain sciences · 2026Article
- Disrupted resting-state interhemispheric functional connectivity in patients with first-episode moyamoya disease.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moyamoya disease (MMD) may lead to perfusion deficits, stroke and brain atrophy in the long-term. Our aim was to analyse whole-brain volumetry of a large cohort of Moyamoya disease patients compared to healthy controls. 3D T1w MRI sequences of adult Moyamoya disease patients treated at our centre between 2016 and 2022 without prior revascularization were analysed for whole-brain volumetry (AssemblyNet) and compared age-controlled to healthy controls. A total of 133 different regions of interest were examined retrospectively for each patient separately by localization, structure and tissue type. All segmentations were subjected to automated and manual quality control. After quality control, 149 hemispheres from 80 Moyamoya disease patients were compared to 258 hemispheres from 129 healthy controls. A significant brain volume loss was observed in Moyamoya disease patients with increasing age, with the greatest reduction seen in bilaterally affected patients with Suzuki grade >3. As direct signs of brain atrophy, significant differences were seen across all regions of interests, emphasized in cortical grey matter with a reduction of 4.4% (95% CI 2.7-6.1%;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.